Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Luo JC, Peng YL, Chen TS, et al
Months 2-6: Rest Period and Potential Continued Effects What the research suggests: Senescent cell clearance is not a one-time event with an immediate endpoint
Coskun 2022 mmc3 Table 3 + mmc1 Table S8 Phase 1 single-ascending-dose study (NCT03841630, n=45, conducted in Singapore)
Areas Without Adequate Human Evidence Long-term cardiovascular safety Long-term neurological safety Endocrine effects beyond selected hormone measurements Effects on glucose regulation in people Immune responses Allergic reactions Genotoxicity Carcinogenicity Effects in people with cancer or precancerous disease Reproductive and developmental toxicity Pregnancy safety Breastfeeding safety Paediatric exposure Medicine interactions Interaction with hormone or sleep treatments Repeated exposure over months or years Product-Quality Risks Incorrect amino-acid sequence Glu and Asp residue-order errors Wrong terminal groups Incorrect free-base or acetate designation Incorrect peptide quantity Deletion-sequence impurities Incomplete deprotection Residual synthesis reagents Residual solvents Peptide aggregates Degradation during transport or storage Unverified microbiological quality Unverified bacterial-endotoxin control Certificates unrelated to the supplied batch No reports does not mean no risk FDAs adverse-event database search found no Epitalon reports through December 2025
Research has documented effects on approximately 4,000 genes, with 59% being upregulated (turned up) and 41% being downregulated (turned down)
US$ 21.80
US$ 21.49
US$ 22.78
US$ 24.00
